Expansion Trial for Axitinib In Head And Neck Cancer
Status:
Completed
Trial end date:
2020-04-09
Target enrollment:
Participant gender:
Summary
This study will be a prospective, single-institution, single-arm phase II study of Axitinib
in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma.
The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously,
with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2
or worse toxicities. This will be followed by clinical and/or radiologic response assessment
after 8 weeks and subsequently every 2 months until disease progression or intolerable
toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center